Endocrinology

HIV-infected patients face increased risk of myocardial infarction, as well as higher risk for ART-associated dyslipidemia and insulin resistance.

The US Food and Drug Administration (FDA) has approved Noven Pharmaceuticals Inc.'s once-daily Brisdelle (paroxetine) capsules to reduce moderate to severe hot flashes and night sweats that can last up to five years in menopausal women.

Recognizing that melatonin secretion from the gastrointestinal (GI) tract improves abdominal pain in irritable bowel syndrome (IBS) but decreases with age, Polish researchers from the Medical University of Lodz aimed to define the effect of administering melatonin in postmenopausal women with different predominating IBS symptoms.

By adopting a comprehensive set of case management policies for the care of diabetic and hyperglycemic patients, Johns Hopkins Hospital improved in-hospital mortality rate, reduced length of stay, and reduced hyperglycemia.

Exposure to insulin glargine and metformin did not cause increased risk of cancer or worse cancer outcomes.

Results of a three-year trial of the experimental GLP-1 receptor agonist albiglutide showed that it had a better effect on HbA1c, fasting blood glucose, and body weight than two comparator drugs.

Prescription-strength doses of vitamin D improve highly prevalent comorbidities among diabetic women, such as depression and pain, and also improve risk factors such as excess weight and high blood pressure.

While the current ADA guidelines recommend targeting HbA1c levels to below 8% for high-risk patients with diabetes, reducing the level to 5.7% dose not raise CVD or overall mortality risk, according to a recent study.

A novel algorithm for patient self-adjustment of prandial insulin dose could make it easier for patients who are poorly-controlled on basal insulin to add meal-time insulin.

In patients with type 2 diabetes currently taking metformin, treatment with combination exenatide plus insulin glargine decreased fasting glucose and resulted in greater weight loss compared to treatment with insulin lispro plus insulin glargine.

Study shows dulaglutide improved glycemic control in patients at 52 weeks compared to sitagliptin, but with a higher rate of adverse events.

Study shows a combination of liraglutide and the genetically modified insulin analog degludec was safe and improved HbA1c levels, weight loss, and hypoglycemia outcomes in patients with type 2 diabetes.

The Diabetes Resource Guide highlights 20 websites that feature articles on topics such as ways to address and improve lifestyle factors (such as diet), how to live day to day with diabetes, information about diabetes medications, online forums, and more.

Hypertriglyceridemia combined with insulin resistance may lead to increased platelet activation in women with polycystic ovary syndrome (PCOS).

Insulin sensitivity improved after three nights of adequate sleep in nondiabetic men after days of inadequate sleep.

Study results suggest that tight glycemic control is associated with decreased length of stay and improved mortality.

Results of a recent meta-analysis suggest lower rates of hypoglycemia with insulin degludec in obese patients when compared with insulin glargine.

Study shows that 12 weeks of vitamin D supplementation in obese adolescents does not affect cardiometabolic risk factors.

At ENDO 2013, an expert panel discussed the consensus statement on the evaluation and treatment of hypertriglyceridemia and the evidence supporting the recommendations.

Study results show improvements in body composition, intrahepatic lipids, and cardiovascular risk markers in obese men treated with growth hormone for six months compared with placebo.

In cell culture and mice studies, bazedoxifene inhibited estrogen-induced gene expression and cell proliferation in cancer cells, including those that were tamoxifen-resistant.

Initial data show similar efficacy but different costs among injectable insulin treatments for patients who fail oral antidiabetic drugs.

A recent study suggests that skipping breakfast in overweight women may lead to insulin resistance.

According to a recent retrospective study, orlistat is not associated with hepatotoxic effects after one year of use and it contributes to weight loss in obese patients.

In patients previously treated with bisphosponate, denosumab was associated with greater improvements in bone mineral density than ibandronate and risedronate.

Phase III studies show LDMP to be safe and effective for treatment of vasomotor symptoms in menopausal women.

As irritable bowel syndrome (IBS) remains a complicated condition to treat with an etiology that's still unknown, it's difficult for physicians to find the best proven therapies among new remedies and the variety of pharmacological and nondrug options they have been trying for years.

Growing evidence suggests increased cardiovascular risk in patients with nonalcoholic fatty liver disease (NAFLD) - in particular nonalcoholic steatohepatitis (NASN) - but no data exists to support a specific management approach.

Inpatient management of patients with increasingly virulent community acquired and nosocomial infections, ranging from bacteremia to C. difficile colitis, presents hospitalists with challenging choices.

Results from a small study indicate patients with difficult-to-treat diabetic peripheral neuropathy (DPN) may benefit from therapy with tanezumab, a humanized monoclonal antibody against nerve growth factor.